Research
Filter News
Found 146,432 articles
-
Molecular Diagnostics Research That Could Transform Healthcare Featured in the January Issue of ADLM's The Journal of Applied Laboratory Medicine
1/3/2024
Molecular diagnostics is a powerful branch of laboratory medicine that examines the fundamental genetic and biochemical components of life to provide invaluable insights into health and disease.
-
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
1/3/2024
Better Therapeutics Inc. and Glooko, Inc. today announced a partnership to integrate Better Therapeutics’ AspyreRx ™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
-
Cystic Fibrosis Rescued by Reprogramming the Cell’s Secretory Machinery
1/3/2024
Porosome Therapeutics, Inc. announced the publishing of a study that brings promise for a cure to cystic fibrosis.
-
SpineX Announces Successful in-Human Results to Treat Adults with Cerebral Palsy
1/3/2024
SpineX Inc. today announced groundbreaking results in its first in-human study treating an adult with Cerebral Palsy (CP).
-
Microgravity offers unique advantages when investigating cells and proteins, but collaboration and a strong ethical framework are needed to fully realize its benefits.
-
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
1/2/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed in a Phase 3 clinical trial of higher dose 9 mg mazdutide, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist, in Chinese adults with obesity.
-
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials
1/2/2024
CSL Behring, a business unit of global biotechnology leader CSL, announced the availability of 4- and 5-gram vial sizes for ZEMAIRA®
-
Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration
1/2/2024
Immorta Bio, Inc. announced today its Personalized Progenitor Cell (PPC) platform and filing of associated intellectual property.
-
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
1/2/2024
Longboard Pharmaceuticals today announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).
-
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery PlatformBioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study
1/2/2024
Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca.
-
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
1/2/2024
Avenue Therapeutics, Inc. today announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy.
-
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
1/2/2024
Citius Pharmaceuticals, Inc. today announced that it has completed enrollment in its pivotal Phase 3 clinical trial for Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.
-
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
1/2/2024
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.
-
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
1/2/2024
Soligenix, Inc. announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections.
-
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
1/2/2024
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.’s (OTCQB: ODYY) (“Odyssey”) proprietary neurological drug therapies and technologies.
-
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
1/2/2024
Voyager Therapeutics, Inc. today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
-
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
1/2/2024
Virios Therapeutics, Inc. today announced receipt of the Food and Drug Administration’s (“FDA”) feedback on requirements for advancing IMC-2 (combination of valacyclovir + celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”).
-
Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate
1/2/2024
Biotechnology company Inventprise Inc.n announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine in young adults.
-
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
1/2/2024
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants.
-
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
1/2/2024
Leap Therapeutics, Inc. today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01.